Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 10:55am ET on Wednesday, August 16, 2017, at Le Parker Meridien in New York.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858-717-2310 Email: [email protected]
